Mário Sousa

[Alberto Averna @AAverna7]

Great science begins with a lab, a team, and of course—pizza! 🍕🧠🔬

[Parkinsonism & Related Disorders @ParkinsonismD]

#MovementDisorderRounds #gait #VSSP #frontallobe #ataxia #cognitive #splenomegaly #parkinsonism

What is the diagnosis ?

Log in :

https://t.co/CNB85xalXD

Expert commentary

https://t.co/ZGoHZDExRN

[Michael Okun @MichaelOkun]

Can you name the 5 treatment recommendations for impulse control disorders in Parkinson's disease? Primum non nocere. There is a brand new expert consensus on their management in @MDJ_Journal which is a must read for all clinicians.
Key points:
- Impulse-control and related behavioral disorders (are common and have a huge impact on persons w/ Parkinson's and caregivers.
- The consequences of failing to identify and treat them are huge.
- The authors sought to establish an international expert consensus on treatment strategies.
- They have established a really nice consensus on establishment of some definitions for severity.
- Regular screening for early detection is huge.
- Treatment: continuous monitoring, involving care partners and seeking 'specialist advice for legal or financial challenges.'
- Mild cases gradual reduction in dopamine agonists first.
- Second-line treatment: 'reversing the last medication change, cognitive behavior therapy, STN DBS and specific medications like quetiapine, clozapine, and antidepressants.'
- The authors also offer recommendations for punding and dopamine dysregulation syndrome.
My take: Impulse control disorders are an important challenge in practice and I believe that every clinician managing persons with Parkinson's should be versed on the information contained in this paper. In particular, clinicians should never prescribe dopamine agonists without a monitoring plan. There should be shared decision making including the care-partner and family who will play the critical role(s) in monitoring. In the treatment of Parkinson's disease I can think of no better example of Primum non nocere, first do no harm. It is our duty to manage and to monitor dopamine agonists and replacement therapies in our persons w/ #Parkinsons.
https://t.co/GDZIwxqPMi @PdAvengers @ParkinsonDotOrg

[Talyta Grippe @TalytaGrippe]

Should we request electrophysiological evaluation to assess movement disorders? Yes!
Very happy to share our latest publication, supervised by @RobertC21093233
Following are some of the highlights! 1/3

[Daniel G. Di Luca @dilucadaniel]

Excited to share this publication describing the effects of GPi/GPe DBS in MSA-P.

Thanks @DrAlfonsoFasano and @MSACoalition.

@WashUNeurology

[Alberto Averna @AAverna7]

Honored to announce that our figure has been selected as the cover image for the June issue of @MDJ_Journal ! Thank you to the amazing team @GerdTinkhauser and contributors who made this possible! #MovementDisorders #Research
https://t.co/WWxpQdHtgo

[Blas Couto @BlasCouto]

Los científicos, divulgadores y conductores de tv @andresrieznik y @euge_lop me entrevistaron sobre la Enfemedad de #Parkinson en su programa que sale esta tarde al aire...

[Gerd Tinkhauser @GerdTinkhauser]

Offene Stelle für unser klinisches Movement Disoders Fellowship ab sofort zu besetzen!

Zentrum für Parkinson und Bewegungsstörungen; Universitätsklinik Bern, Schweiz

Wir freuen uns auf Eure Bewerbung

Vielen Dank für das Verbreiten der Nachricht!

https://t.co/ruy2VaP2VE

[MDS @movedisorder]

Top articles from @MDJ_Journal:
1. Spectral Topography of the Subthalamic Nucleus
https://t.co/YGvie2iFP6
2. Double-Edged Effects of Venglustat on Behavior
https://t.co/NO8kuiwoBE
3. Ca2+–Calmodulin–Calcineurin Signaling Modulates α-Synuclein Transmission
https://t.co/QdJ7jdt0Sm

[Movement Disorders Journal @MDJ_Journal]

A unique detailed map of the STN derived from local field potentials of 70 PD patients offers new insights into hot spots for various frequency bands and for optimal clinical response (rigidity). https://t.co/Fha16iLCLG

[Alberto Averna @AAverna7]

Excited to share our latest @MDJ_Journal paper, on the spectral topography of the STN in Parkinson’s disease to inform next-generation sensing-based DBS. #research #Parkinsons #dbs
https://t.co/pdGlVPIlRH
@GerdTinkhauser @mar10sousa @ElenaBernasco @duchetb @InesDebove

[Movement Disorders Clinical Practice @MDCP_Journal]

Clinical pearl: A statistical algorithm determined which factors warrant directional testing in DBS for #PD https://t.co/7sbSRy7lV7

From the newly published research article "Deep Brain Stimulation: When to Test Directional?" https://t.co/sN6J00A7hW

@InesDebove

[Rui Araújo @rmmaraujo]

Clinical Picture | Searching for subtle signs in Parkinson's disease https://t.co/7jBz1PUk7W via @YouTube
@FMUPorto

[Daniel G. Di Luca @dilucadaniel]

Excited to share the results of our STEADY-PDIII and SURE-PD3 trial analysis.

When it comes to inclusion in large PD trials, NIH mandates matter.

@NINDStrials @NINDSDiversity @NeurologyCP

[Gabor G. Kovacs MD PhD FRCPC @GGKovacsBrain]

Creation of a Progressive Supranuclear Palsy Centre in Toronto:
https://t.co/FG4blSZCSC

[Rui Araújo @rmmaraujo]

Movement disorders are particularly complex movement-related complications — making them especially difficult to diagnose, treat and understand. That is why we are promoting #MoveDisorder awareness.
Join us on a live event 29 November 2022
https://t.co/1WWbFeOWMF

[The Lancet Neurology @TheLancetNeuro]

NEW ONLINE: review by @rmmaraujo of @EWijdicks new book, Neurocinema: The Sequel—A History of Neurology on Screen https://t.co/sHnR6eJGa8

[Movement Disorders Clinical Practice @MDCP_Journal]

Pseudogenes, previously considered meaningless, can interfere with genetic testing, affect gene expression, and induce mutations. @FraMagrinelli reviews what clinicians need to know about these "genomic fossils". https://t.co/49iIOK6iPB

[Gabor G. Kovacs MD PhD FRCPC @GGKovacsBrain]

Introducing the concept of protracted course Progressive Supranuclear Palsy: this operationalizes in two categories, clinical and neuropathological and provides a framework to investigate the biology underlying long duration of disease.
https://t.co/emVAJyusa7

[Gabor G. Kovacs MD PhD FRCPC @GGKovacsBrain]

Novel conditions for seeding assay distinguishes synuclein seeding in MSA from Lewy body disorders. Moreover, MSA brains show seeding heterogeneity. SEE: https://t.co/D1jzeRMuBO
BTW: For clinical translation, see: https://t.co/7WmiGLlSCU